(HealthDay is the new name for HealthScoutNews.)
WEDNESDAY, July 9, 2003 (HealthDayNews) -- A blood test may one day help predict which people with potentially early symptoms of multiple sclerosis will go on to develop the disease.
The test has generated some cautious optimism among scientists because it's quick, easy and the results, albeit in a relatively small and homogenous group of people, were quite accurate.
The results of the study are outlined in the July 10 issue of the New England Journal of Medicine.
"It's important to keep in mind that this is very much a preliminary data set and so it is not yet ready for prime time in terms of flying as a diagnostic test," says Dr. Amit Bar-Or, author of an editorial in the same issue of the journal.
"People have identified in the past tests that might serve a similar purpose only to find later on that they didn't have the same kind of accuracy that they hoped," adds Bar-Or, an assistant professor of neurology and neurosurgery at the Montreal Neurological Institute.
Multiple sclerosis is thought to be an autoimmune disease that affects the central nervous system. The most common characteristics of the disease include fatigue, weakness, spasticity, balance problems, bladder and bowel problems, numbness, vision loss, tremor and vertigo.
Most patients who are eventually diagnosed with multiple sclerosis first seek help with symptoms suggestive of MS -- called "clinically isolated syndrome" -- that cannot yet be definitively diagnosed.
"Diagnosis is difficult and there is no single test that can tell you whether or not you have MS," says Stephen Reingold, vice president for research programs at the National Multiple Sclerosis Society. "Many people who end up having MS have signs and symptoms that could be a dozen different things," such as stroke or brain tumors.
Diagnosis can take years and, during that time, treatment is often put on hold. "One of the challenges is that there are drugs that can treat MS and a general sense that the sooner you treat it the better you are," Reingold says. "The question then is ... what can you do to speed the time to say this person has MS?"
There are some techniques to help with diagnosis, notably magnetic resonance imaging -- or MRI -- to detect telltale lesions in the brain, but nothing that does so with overwhelming accuracy.
The authors of the new study looked at 103 patients who had had a "clinically isolated syndrome," along with positive findings for lesions on their MRIs and on a test of their cerebrospinal fluid.
The patients were then tested for antibodies against myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP), two brain proteins that scientists know are involved in MS.
Eighty-three percent of patients who tested positive for the anti-MOG antibodies and 95 percent of those who tested positive for both anti-MOG and anti-MBP antibodies had a relapse within approximately one year. Three quarters (77 percent) of those who tested negative for both anti-MOG and anti-MBP antibodies did not suffer a relapse during that period.
It's very likely that all the patients in the study, given their MRI and spinal fluid results, would have received a certain diagnosis of MS in five to 10 years. This test simply showed that they were likely to have a relapse leading to a definite clinical diagnosis of MS within one year if they tested positive for both antibodies.
"Being able to have a greater sense of confidence earlier on that an individual will end up with a diagnosis of MS, once substantiated, would allow us to recommend therapies at the earliest stages," Bar-Or says.
"Once you have a clinical diagnosis, then you are in a position to be able to make treatment choices and the best data we have suggests that the earlier you treat, the better," Reingold adds.
Having a blood test such as this may cut the diagnosis time a bit. But it's important to note that MRIs already provide some of the necessary information used for a diagnosis of MS. And some drugs are approved to give to patients even before their diagnosis is definitive, Reingold says.
It would be interesting to see if the antibody test ultimately proves more effective than an MRI, Reingold says.
"One wants to appropriately balance out the excitement about this type of approach with how early it is," Bar-Or cautions.
More information
For more on MS, visit the National Multiple Sclerosis Society or the Multiple Sclerosis International Federation.